Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2.
Int J Biol Macromol
; 227: 896-902, 2023 Feb 01.
Article
in English
| MEDLINE | ID: covidwho-2158946
ABSTRACT
As SARS-CoV-2 variants of concern (VOC) reduce the effectiveness of existing anti-COVID therapeutics, it is increasingly critical to identify highly potent neutralizing antibodies (nAbs) that bind to conserved regions across multiple variants, especially beta, delta, and omicron variants. Using single-cell sequencing with biochemical methods and pseudo-typed virus neutralization experiments, here we report the characterization of a potent nAb BD-218, identified from an early screen of patients recovering from the original virus. We have determined the cryo-EM structure of the BD-218/spike protein complex to define its epitope in detail, which revealed that BD-218 interacts with a novel epitope on the receptor-binding domain (RBD) of the spike protein. We concluded that BD-218 is a highly effective and broadly active nAb against SARS-CoV-2 variants with promising potential for therapeutic development.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
SARS-CoV-2
/
COVID-19
Topics:
Variants
Limits:
Humans
Language:
English
Journal:
Int J Biol Macromol
Year:
2023
Document Type:
Article
Affiliation country:
J.ijbiomac.2022.12.120
Similar
MEDLINE
...
LILACS
LIS